Just over a week after Roche was forced to initiate a Europe-wide
recall of HIV drug Viracept (nelfinavir), in-PharmaTechnologist.com
considers the contamination case and the pharmaceutical processes
blamed for the incident.
After dismal second quarter results Patheon is stepping up its
resolve for 'damage control' and indicated that further cutbacks at
its problematic Puerto Rico plant are imminent.
The pharmaceutical and healthcare industries will help to push
trade between India and the United Kingdom up by 60 per cent within
three years, claims a soon-to-be released report.
The European Commission has released figures showing that there has
been a dramatic and concerning increase in pharmaceutical
counterfeiting, with seizures in Europe hitting an all time high of
over 2.5m items.
The fine chemicals division of Japanese contract manufacturer Daiso
has taken out a license to a highly-selective technology used to
synthesise chiral molecules.
Contract manufacturer Granules India is moving towards vertical
integration, with a new tabletting facility scheduled to come
onstream this August at the company's Gagillapur site near
Hyderabad in India.
Lonza is betting on the growth of antibody-drug conjugates as the
way-of-the-future cancer treatments by moving to large scale
production of the emerging drug class by 2008.
An online database detailing information on all manufacturing and
importation certificates and authorisations issued within the
European medicines network has been launched by the European
Medicines Agency (EMEA).
Solvay Pharmaceuticals has sold two of its manufacturing facilities
that it no longer considers as core. The new owners will now act as
a contract manufacturer for Solvay, the company announced today.
Canadian contract manufacturer Patheon has announced its plans to
restructure its Ontario network of drug manufacturing facilities in
order to improve its profitability.
Canadian contract manufacturer Patheon has announced a $150m
(€114m) investment by a private equity firm - a move the company
sees as the best viable option to end its financial misery.
Shire Pharmaceuticals' plans to buy New River Pharmaceuticals will
eventually affect a contract manufacturing arrangement with Albany
Molecular Research (AMR).
Indian chemical firm Syschem is planning to splash out up to $15m
(€11.4m) over two years to expand its manufacturing capacity – a
move the company said will facilitate its smooth entry into the
pharma industry and help cope with...
Australian contract manufacturing organisation (CMO) Eastland
Medical Systems has bagged a manufacturing and distribution
contract with UK's Proto-Pharma for its anti-malaria treatment.
Actavis has waded further into India and picked up new contract
manufacturing capabilities along the way with the purchase of a
division of Sanmar Specialty Chemicals (SSCL).
Pfizer's latest cutbacks will provide a new outsourcing opportunity
for contract manufacturing organisations (CMOs) in low-cost
destinations as the drug giant announces plans to double its amount
of drug production outsourcing.
Cardinal Health is about to sell its drug manufacturing arm to an
international private investment firm, only two months after
announcing its decision to divest the segment, while its second
quarter earnings doubled as a result.
A multi-million dollar US manufacturing contract for Acambis hinges
on whether or not the firm can satisfy the Food and Drug
Administration (FDA) that its investigational smallpox vaccine
should be approved.
A new player has entered the pharma formulation development
services arena, offering technologies used in the food industry to
improve drug palatability.
A new Special Economic Zone (SEZ) is being created by Indian firm
JB Chemicals & Pharmaceuticals for the contract manufacturing
of active pharmaceutical ingredients (APIs), intermediates and
finished drug formulations.
More and more drug makers are turning to reformulation to prolong
the lifecycle of their top sellers and protect precious revenue
from generic copies, as well as supplement dwindling pipelines.
The booming pharmaceutical contract research market sees a new
player enter the arena as analytical lab Eno River Labs separates
into two independent divisions to create a new business that will
provide analytical and formulation...
Eli Lilly has signed a new agreement with drug delivery specialist
Alkermes for the manufacture of its new inhaled insulin drug - AIR
- in advance of the product's market launch.
India's drug manufacturing industry is tipped to grow 10 per cent
over the next three years as more pharma firms shift operations
there to cut costs, says a research report.
Solid oral dose product specialist Almac Pharma has announced it
has expanded its formulation facilities located at its UK
headquarters to provide a wider range of services to pharma and
biotech companies.
Crucell yesterday announced it had received the first orders from
US-headquartered Wyeth Biotech. The order represents the first move
following the finalisation of the contract manufacturing agreement
between the two companies at...
AAIPharma has announced it has signed a contract manufacturing
agreement with Mallinckrodt Pharmaceuticals Outsourcing which aims
to provide a "one-stop drug development solution" for drug makers.
Biotech company Progen has decided to manufacture its new
anti-cancer drug in-house rather than outsource it in order to save
on costs after the FDA gave the thumbs up for the manufacture of
the drug for its upcoming phase III clinical...
Dutch biotech company Crucell said last week that it had completed
its acquisition of SBL Vaccin in an agreement worth €39.4m, but
remained tight-lipped about its plans for the Swedish firm's
contract manufacturing business.
Singapore has successfully completed the first phase of its
biomedical science (BMS) initiative and is now pushing the second
phase forward in order to drive growth in its pharma industry
further.
Drug giant GlaxoSmithKline (GSK) has been awarded a contract with
the US government to supply 800,000 doses of flu vaccine to the US,
where a bird flu pandemic still remains a threat.
Lonza has signed two separate deals with California-based Genentech
- a move that illustrates the re-emergence of a relationship
between the two firms.
US-based drug maker Cleveland BioLabs has teamed up with
biopharmaceutical manufacturer Synco Bio Partners to produce its
leading radioprotection molecule for clinical trials and
commercialisation
Although manufacturing is the most established of the pharma
outsourcing segments, many service areas are still rapidly
evolving. OutsourcingPharma.com gives a brief run down of the
current state of play.
Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract
Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...
